The RUO Website Compliance Checklist: What FDA Warning Letters Actually Flag

Written by

in

RUO peptide website compliance is usually treated as a wording question: which disclaimer to use and where to put it. The FDA warning letters sent to peptide sellers in 2026 show that the question is wider. In each one the agency acknowledged the research-use-only (RUO) label, then quoted the seller’s own website to show what the products were intended for. This guide is for owners and marketers of RUO peptide stores. It summarises what those letters cited, sets out what ad platforms and payment processors read on the same pages, and ends with a 25-point site audit. It is marketing and policy information, not legal advice.

Key takeaways
  • The website was the evidence. All six 2026 letters we read rest on text and products found on the seller’s own site.
  • The disclaimer was noted and set aside. Each letter records the research-use wording, then says the site shows the products are intended as drugs for people.
  • Research framing did not protect a claim. Lines built on “studied for” or “research shows” were quoted as evidence of intended use.
  • Supplies counted. Bacteriostatic water sold next to peptides was cited in five of the six letters, and charged as a drug in four.
  • Some things were not cited. None of the six letters quotes a testimonial, an image or a social post. US and UK rules still reach them.
  • Platforms and processors read the same pages and apply their own rules, whatever the label says.
  • An audit makes the site match the business. It does not make a business selling for personal use compliant.

1. Why the website is the evidence

Under US law, whether a product is a drug depends on its intended use, not on what the label calls it. The regulation the 2026 letters cite is 21 CFR 201.128. It says intended use means the objective intent of the people responsible for the product. That intent can be shown by what they say, by the design or composition of the product, and by the circumstances in which it is distributed. The regulation gives labeling claims, advertising matter, and oral or written statements as examples.

A website is all of those at once. Product pages, comparison articles, the navigation menu, the items in the catalogue and the tools on the site are statements made by the seller. A reviewer does not need inside information. They need a browser and a date.

That is how the 2026 letters were built. Each one says the FDA reviewed the firm’s website in a stated month, lists product page URLs, and quotes text from them. None of the six relies on an inspection, a test purchase or a lab result.

Who else reads the site

The same pages are read by Google’s ad and Merchant Center review, by your payment processor’s risk team, and, if you sell to the UK, by the MHRA and the ASA. Their rules differ, but they share one feature: none of them accepts the seller’s label as the last word.

2. What the 2026 FDA warning letters cited

We read six warning letters that the FDA’s Center for Drug Evaluation and Research sent to peptide sellers in 2026. Four are dated 24 August 2026, which we confirmed on fda.gov. Each of those four says the firm’s website was reviewed in July 2026. The other two are dated 31 March and 17 June 2026. All six came from the Office of Unapproved Drugs and Labeling Compliance. There may be other 2026 letters we have not read.

The charge is the same in each. The products are drugs because of their intended use, they are new drugs without an approved application, and introducing them into interstate commerce violates the Federal Food, Drug, and Cosmetic Act. Each firm was asked to reply within fifteen business or working days, and warned that failure to correct violations could lead to legal action, including seizure and injunction.

LetterDateSite evidence the FDA cited, in our words
Gram Peptides31 March 2026Product-page text on appetite, body weight, glucose and lipids. Bacteriostatic water sold alongside peptides that need reconstitution, and charged as a drug.
Wholesale Peptide17 June 2026Product-page text naming prostate conditions, with benefits introduced by “research shows”. Text on testosterone production and cancer research.
Peak Performance Peptides24 August 2026Product-page lines framed as “studied for” or “investigated for” effects on glycemic control, appetite and fat distribution. Bacteriostatic water charged as a drug.
Peptide Partners LLC24 August 2026Product-page summaries of studies suggesting benefits for bone, kidney and brain health. A “reconstitution solution” charged as a drug.
Royal Peptides LLC24 August 2026Comparison pages with benefit lists and clinical results, including the phrase “Once-weekly injection for convenience”. A mixed multi-pack kit and a blend. Bacteriostatic water marketed beside a peptide guide and a peptide calculator.
TXP Innovations LLC dba Tex Peptides24 August 2026Product-page text on supporting weight loss and managing type 2 diabetes and obesity. Bacteriostatic water marketed as a solvent for the site’s products, and charged as a drug.

The patterns across the six letters

  • Product-page claims are the core. Every letter quotes product or comparison pages. Statements about weight, appetite, blood sugar, named diseases or body function are treated as evidence of intended use.
  • Research phrasing did not change the reading. Several of the quoted lines are written as descriptions of studies. The FDA quoted them anyway.
  • Reconstitution supplies are evidence. Five letters cite bacteriostatic water or a reconstitution solution sold next to the peptides. Four charge the water itself as an unapproved drug, reasoning that the pairing shows it is meant for injection.
  • Tools and bundles appear. One letter cites a peptide guide and calculator, a mixed kit and a blend.
  • The catalogue repeats. Semaglutide, retatrutide, tesamorelin, PT-141 and SS-31 are named in all four August letters, and tirzepatide in three.
  • The disclaimer is acknowledged in a footnote. Section 3 covers this.
What the letters did not cite

None of the six letters quotes a customer testimonial or review, describes an image, or cites a social media account, hashtag, email or discount code. None mentions syringes. The reviews covered websites. This matters for accuracy: articles that say the FDA “flagged testimonials and Instagram” in these letters are not describing these letters. Sections 5 and 8 explain why those areas still belong in an audit.

3. Why a disclaimer alone is not enough

Every one of the six letters records that the firm’s labeling marketed the products for research use only and not for human consumption, or close variants of that wording. Each then says that the evidence from the website establishes the products are intended to be drugs for human use. The disclaimers were present and the FDA saw them. They did not decide the outcome.

The FDA has said the same thing to consumers. Its page on unapproved GLP-1 drugs, updated on 1 October 2026, says the agency has warned companies selling certain products it describes as “falsely labeled” for research purposes or as not for human consumption, and that these were sold directly to consumers for human use with dosing instructions.

The reasoning follows from section 1. A disclaimer is one statement. Intended use is judged on all the statements and circumstances together. If a footer says “for laboratory research only” and the product page above it describes appetite and body weight, the two conflict, and the reviewer goes with the weight of the page.

What a disclaimer is for

A research-use statement is worth having when it is true. It tells a genuine research buyer what the product is and is not, and it should appear on the product page, the label, the checkout and the terms of sale. It works as a summary of how the business operates. It does not work as a correction to the rest of the site.

The same logic limits what an audit can do. Removing claims from a site that still sells to people buying for personal use changes the wording and leaves the circumstances of distribution untouched, and the regulation counts those circumstances too. This guide is about making a site consistent with a real research-supply business. We do not help disguise human-use sales, and no wording would do that reliably anyway.

4. Product copy, comparison pages and blog content

Product pages

The quoted text in the letters has a common shape: it tells the reader what the compound does in a body, or which condition it relates to. A research supplier’s page has a different job. It identifies the material and documents its quality. The table shows the difference by area.

Area of the pageReads as intended for human useConsistent with a research-supply business
Product nameNames built around a drug class or an outcomeThe compound’s accurate chemical or common name, matching the label and certificate of analysis
DescriptionEffects on weight, appetite, sleep, recovery, ageing or a named conditionIdentity, sequence or formula, molecular weight, quantity, form, stated purity
Study summariesBenefit lists drawn from trials, whatever phrase introduces themNone on the sales page. Analytical data for the batch instead
Usage informationAmounts, schedules, routes, or mixing steps for useStorage and handling as supplied, and safety data sheet information
DocumentationA purity badge with nothing behind itA batch-specific certificate of analysis and the test method
Research-use statementA footer line that contradicts the page above itA statement on the page, label and checkout that matches everything else

Two details from the letters are worth applying directly. First, phrases such as “studied for” and “research shows” did not turn a benefit statement into something else. Second, one letter quoted text under a heading about advanced research use that listed anti-ageing and neuroprotection. A research heading over an outcome list is still an outcome list.

Comparison pages and blog content

One August letter cites two comparison pages by URL. One address contains a weight-loss phrase, and the quoted text includes benefit lists and trial results. They sit outside the shop section, like blog posts. The lesson is that everything on the domain counts, not just product pages.

For a blog on an RUO store, our standard is:

  • No articles that compare compounds by outcome for a person, or that explain how to choose between them.
  • No articles on protocols, cycles, schedules or results.
  • No outcome or condition words in URLs, page titles or meta descriptions. They are statements too.
  • Topics that fit the business: analytical methods, how to read a certificate of analysis, storage and stability, shipping and documentation.
  • Old posts get the same review as new ones. An archived article is still published.

5. Testimonials, reviews, images and social links

These areas were not cited in the six letters. They are still statements or circumstances connected to the seller, so they fall inside the intended-use regulation, and other reviewers name them directly. The MHRA’s guidance, covered in section 8, lists websites, social media and customer reviews among the things it looks at.

Testimonials and reviews

A review that describes a personal result is a human-use statement displayed on your product page. You did not write it, but you chose to publish it. For a research supplier, reviews that make sense are about the things a lab buyer can judge: documentation, packaging, delivery time and service. If your review tool imports text automatically, moderate it against a written rule, and apply the rule to every review, not only to the ones that look risky. Do not write, buy or edit reviews.

Images

Images make claims without words. Body or before-and-after imagery, lifestyle photography, and pictures of injection equipment or a product being prepared for use all say who the product is for. An accurate photograph of the item as sold, with its real label, says what it is. Check alt text and file names as well, because they are published text.

Social links

A social icon in the footer joins that account to the site. If the account, its bio, its hashtags or its reposts talk about personal use or results, a reviewer following the link will read them as the seller’s statements. The same applies to affiliates and anyone paid to promote the store: what they say for you is said on your behalf. Link only to accounts you would be content to have read alongside your product pages.

6. Dosing language, calculators and bundled supplies

This is the area where the 2026 letters are most specific.

  • Bacteriostatic water. Five of the six letters cite it. Four go further and charge the water as an unapproved drug, on the reasoning that selling it to reconstitute the site’s peptides shows it is intended for injection.
  • Calculators and guides. One letter notes the water was marketed alongside a “peptide guide” and a “peptide calculator”.
  • Kits and blends. The same letter cites a mixed multi-pack of two compounds and a pre-combined blend.
  • Dosing language. The FDA’s consumer page describes these products as sold with dosing instructions. One letter quotes a line about weekly injection.

Read together, these describe what regulators call the circumstances of distribution. A catalogue of single-use retail vials, a mixing liquid, a tool that converts amounts, and a multi-pack is a picture of a consumer product, whatever each page says. The letters also explain why the FDA cares: they note that injectable products are delivered directly into the body and bypass its natural defences.

Our position

An RUO site should carry no dosing, administration or reconstitution-for-use content, no calculators, and no bundles assembled around personal use. Whether to sell ancillary supplies at all is a business and legal decision for the owner and their counsel. We will not suggest moving these items to a second domain or a hidden page. The letters show how such supplies are read, and relocating them does not change what they are sold for.

7. What ad platforms and payment processors look at

Google Ads and Merchant Center

Google’s Healthcare and medicines policy for ads has an Unapproved substances section that applies “regardless of any claims of legality”. Its list includes non-government-approved products marketed as safe or effective for a disease, products that imply they work as well as prescription drugs, products with names confusingly similar to an unapproved pharmaceutical or controlled substance, and products that have been subject to government or regulatory action or warning. Merchant Center’s Healthcare and medicines policy uses the same wording for product listings.

Three practical points follow:

  • The landing page is reviewed, not only the ad. The policy refers to landing pages and websites throughout. A clean ad pointing at a page with outcome claims is a page problem.
  • A warning letter is itself a policy trigger. The regulatory-action bullet means that compounds named in FDA letters carry extra risk in ads and feeds.
  • Review must see what buyers see. Google’s Abusing the ad network policy does not allow ads, content or destinations that try to trick or circumvent its review processes. Showing reviewers a different page from the one customers get is a violation in its own right.

Google’s Misrepresentation policy also covers unreliable claims, meaning inaccurate claims or ones that present an improbable result as likely. For the campaign side, see our guides to Google Ads for peptides and Google Shopping for peptides. If your account already has a suspension, start with Merchant Center recovery. Earlier guides in this series cover appealing a Google Ads suspension and setting up Performance Max with policy-safe creative.

Payment processors

Processors publish their own lists, and they read your site when you apply and again when they review the account. Two public examples:

  • Stripe’s prohibited and restricted businesses list prohibits “Incorrectly labeled research chemicals”, along with pseudo-pharmaceuticals that are not safe or make harmful claims. It restricts card-not-present sales of pharmaceuticals and prescription-only products.
  • PayPal’s Acceptable Use Policy prohibits transactions involving products that present a risk to consumer safety, and requires pre-approval to sell products that need a prescription.

Neither page names peptides. Both are written broadly enough that the outcome depends on what an underwriter concludes from your website and your description of the business. That description must be accurate. Telling a processor you sell something else is misrepresentation and puts funds at risk. Our peptide payment processing guide covers how to approach this openly.

Email

Emails are written statements by the seller, and they get forwarded. Hold campaigns, flows and subject lines to the same standard as product pages. Our peptide email marketing guide covers this within RUO framing.

8. A short UK note: ASA and MHRA

If you sell to UK customers or run a UK company, two bodies matter.

The MHRA decides what is a medicine. The Human Medicines Regulations 2012 define a medicinal product in two ways: by presentation, as something presented as preventing or treating disease, and by function, as something that may be administered to modify a physiological function through pharmacological, immunological or metabolic action. The MHRA’s borderline products guidance says it looks at explicit and implicit claims, the properties of the ingredients, how consumers would use the product, and how it is presented, including websites, social media and customer reviews. The page does not say that a disclaimer settles the question. Regulation 279 prohibits advertising a medicinal product that has no marketing authorisation.

The ASA regulates advertising. Section 12 of the CAP Code allows medicinal claims only for licensed products and bars advertising prescription-only medicines to the public. The Code’s scope covers a company’s own website and, for UK-registered marketers, its non-paid social media. CAP’s advice on prescription-only medicines, dated 30 September 2026, says almost any reference to such a medicine is likely to be treated as promoting it, that landing pages count, and that references in posts, images and hashtags can count too. Several catalogue names in the US letters are prescription-only medicines in the UK, so product naming is an advertising question there.

9. The 25-point site audit

The infographic groups the audit by area. Each point is a question to answer with yes or no about your live site.

RUO website audit: 25 points in 6 areas

A. Product pages

1Product names are the accurate compound names and match the label and certificate of analysis.
2Descriptions give identity, quantity, form and purity, with no effect or outcome statements.
3No disease, condition or body-function wording, including under “studied for” or “research shows”.
4No study or trial summaries on sales pages.
5A batch-specific certificate of analysis is available for each product.

B. Blog and site content

6No comparison articles that rank compounds by outcome.
7No protocol, schedule, cycle or results content, including old posts.
8URLs, page titles and meta descriptions contain no outcome or condition words.
9FAQ and help pages answer supply questions only, not use questions.

C. Reviews and images

10Published reviews cover service, delivery and documentation, not personal results.
11A written moderation rule exists and is applied to every review.
12No reviews are written, bought or edited by the business.
13Images show the product as sold. No body, lifestyle or injection imagery.
14Alt text and image file names contain no use or outcome wording.

D. Catalogue and supplies

15No dosing, administration or reconstitution-for-use instructions anywhere on the domain.
16No calculators or conversion tools.
17No kits, stacks or bundles assembled around personal use.
18The decision on ancillary supplies has been taken with legal advice and recorded.

E. Off-site and channels

19Every linked social account, bio and hashtag set meets the same standard as the site.
20Affiliate and partner content has written rules and is checked.
21Emails, flows and subject lines carry no claims or use language.
22Ads, feed data and landing pages say the same thing, and reviewers see what buyers see.

F. Statements and operations

23The research-use statement appears on the page, label, checkout and terms, and nothing contradicts it.
24The business description given to processors and platforms is accurate.
25There is a dated change log, a named owner for site content, and a repeat audit on the calendar.
A “no” is a page to fix. A site that passes describes the business accurately. It is not legal clearance.

How to run it

Audit steps
  1. Read the primary sources first. Open two or three of the FDA letters linked above and read the quoted site text yourself.
  2. List every published URL. Use your sitemap and a crawl. Include blog posts, category pages, PDFs, old landing pages and anything not linked from the menu.
  3. Go through the 25 points page by page. Record yes or no, with the URL, for each one.
  4. Search the site for outcome and use words. Search for condition names, body-function words and use verbs. Check page titles, meta descriptions and alt text as well as body copy.
  5. Check what is connected to the site. Social profiles, review widgets, email templates, affiliate pages and any marketplace listings.
  6. Fix the page, not its visibility. Correct or remove the content for all visitors. Do not hide it from reviewers, and do not move it to another domain.
  7. Align the channels. Update the product feed, ad copy and email flows so they match the corrected pages.
  8. Take the legal questions to a lawyer. Catalogue decisions, supplies, terms of sale and any regulator correspondence need an attorney who works in FDA or UK medicines law.
  9. Log and repeat. Keep a dated record of each change. Re-run the audit every quarter and after any redesign, plugin change or new product launch.

10. FAQ

What is RUO peptide website compliance?

It means the whole website is consistent with a business that supplies materials for laboratory research. Product copy, blog content, reviews, images, supplies and linked accounts are all read as evidence of intended use, so compliance covers all of them, not just the disclaimer.

Is a “research use only” disclaimer enough to protect a peptide site?

No. Each of the six 2026 FDA warning letters we read notes the seller’s research-use labeling, then says website evidence shows the products are intended as drugs for human use. A disclaimer is one statement among many and is weighed with the rest of the site.

What did the August 2026 FDA warning letters to peptide sellers cite?

The four letters dated 24 August 2026 cite product-page and comparison-page text about effects on the body, and bacteriostatic water or a reconstitution solution sold alongside the peptides. One also cites a peptide guide, a calculator, a mixed kit and a blend.

Did the FDA letters cite testimonials or social media?

Not in the six letters we read. None quotes a testimonial, describes an image or cites a social account. Those areas can still count as evidence of intended use under 21 CFR 201.128, and the MHRA’s UK guidance lists social media and customer reviews by name.

Can we keep health claims if we write “studies suggest” in front of them?

The letters indicate not. Several of the lines the FDA quoted were framed as “studied for”, “investigated for” or “research shows”. The agency treated them as evidence of intended use regardless of the framing.

Should an RUO store sell bacteriostatic water?

That is a decision to take with legal advice. Five of the six letters cite it as evidence, and four charge it as an unapproved drug because it was sold to reconstitute the site’s peptides. Moving it to another domain does not change that reading.

Do Google and payment processors accept the RUO label?

Not on its own. Google’s Unapproved substances policy applies regardless of any claims of legality, and it reviews landing pages. Stripe prohibits incorrectly labeled research chemicals. Both judge what the site shows.

Does passing this audit mean the site is legal?

No. The audit checks that the site describes a research-supply business accurately and consistently. It is marketing and policy information, not legal advice, and it cannot make a business that sells for personal use compliant.

Want a second pair of eyes?

Have your site read the way a reviewer reads it

Peptide Marketing works only with research-use-only peptide brands. We will go through your site against the 25 points, show you which pages a regulator, ad platform or processor would quote, and tell you plainly what to change first. We do not cloak pages, disguise product names or hide content from reviewers.

Book a 15-min call

Prefer email? Write to hello@peptidemarketing.info.

Sources

This guide is marketing and platform-policy information for businesses selling research-use-only products. It is not legal or regulatory advice. Sources were read in November 2026. Laws, letters and policies change, so check the linked pages and take advice from a qualified attorney before you act.

Comments

8 responses to “The RUO Website Compliance Checklist: What FDA Warning Letters Actually Flag”

  1. […] nothing about them. Fix the site first. Then build keywords that describe it accurately. Our RUO website compliance checklist covers what to […]

  2. […] sent warning letters to peptide sellers in 2026, and processors read the same letters you do. Our RUO website compliance checklist summarises what those letters […]

  3. […] to bacteriostatic water sold alongside the products, and in one case a kit with a syringe. Our RUO website compliance checklist covers what those letters flag across the whole […]

  4. […] apply to your catalogue. Our Google Ads for peptides page covers the wider policy picture, and the RUO website compliance checklist covers the site […]

  5. […] “research use only” label is one piece of evidence. It does not outweigh the rest. Our RUO website compliance checklist covers what that means for your own […]

  6. […] letter (24 August 2026) quote product-page text about body weight, glucose and diabetes. Our RUO website compliance checklist summarises six of these […]

  7. […] If a page is blocked, unindexed, thin or vague, no AI-specific trick fixes it. That is why our RUO website compliance checklist and our product-page work come before anything labelled […]

  8. […] RUO website compliance checklist […]

Leave a Reply

Your email address will not be published. Required fields are marked *